(Q34774478)

4 August 2017

1 reference

title

Graves' ophthalmopathy: a rational approach to treatment (English)

1 reference

4 August 2017

Wilmar M Wiersinga

1

1 reference

4 August 2017

Mark F Prummel

series ordinal

2

1 reference

4 August 2017

publication date

1 September 2002

1 reference

Trends in Endocrinology and Metabolism

4 August 2017

published in

1 reference

4 August 2017

volume

13

1 reference

4 August 2017

issue

7

1 reference

4 August 2017

page(s)

280-287

1 reference

An evidence-based approach to the treatment of Graves' ophthalmopathy

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Test-retest reliability of the GO-QOL: a disease-specific quality of life questionnaire for patients with Graves' ophthalmopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Animal models of Graves' disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Epidemiology and prevention of Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Graves orbitopathy: correlation of CT and clinical findings

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Dysthyroid optic neuropathy. The crowded orbital apex syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Graves ophthalmopathy: MR evaluation of 10-Gy versus 24-Gy irradiation combined with systemic corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Perspective--Part III: retrobulbar irradiation in Graves orbitopathy: the Dutch experience

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Orbital Cobalt Irradiation Combined with Systemic Corticosteroids for Graves' Ophthalmopathy: Comparison with Systemic Corticosteroids Alone*

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Lanreotide in the treatment of patients with thyroid eye disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Beneficial effect of pentoxifylline on thyroid associated ophthalmopathy (TAO)*: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Antioxidant agents in the treatment of Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Therapy of Graves' ophthalmopathy with intravenous high-dose steroid followed by orbital irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Intravenous methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Probable risk of tumour induction after retro-orbital irradiation for Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Probable risk of tumor induction after retro-orbital irradiation for Graves' ophthalmopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Radiation retinopathy after orbital irradiation for Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Radiation retinopathy after standard radiotherapy for thyroid-related ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Coronal approach for rehabilitative orbital decompression in Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Treatment of proptosis with fat removal orbital decompression in Graves' ophthalmopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Early strabismus surgery for thyroid ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

A single technique to correct various degrees of upper lid retraction in patients with Graves' orbitopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Botulinum toxin A treatment of overactive corrugator supercilii in thyroid eye disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Natural history of thyroid associated ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

Cytokines in thyroid eye disease: potential for anticytokine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2802%2900622-7

7 January 2021

10.1016/S1043-2760(02)00622-7

Identifiers

DOI

1 reference

4 August 2017

1 reference